ASH 2022 | Outcomes of patients with B-ALL with concomitant Ph+ and CRLF2 rearrangements
Nitin Jain, MD, University of Texas MD Anderson Cancer Center, Houston, TX, outlines results from a retrospective analysis of patients with B-cell acute lymphoblastic leukemia (B-ALL) with concomitant BCR-ABL1 and CRLF2 rearrangements. The analysis found that treating this subgroup of patients with immunotherapy plus tyrosine kinase inhibitors (TKI) cleared the Ph+clone but the CRLF2-rearranged clone still persisted, which likely causes relapse of the disease. Overall, patients who harbor concomitant Ph+ and CRLF2 rearrangement represent a rare but high-risk subgroup of B-ALL, thus more tailored management and earlier transplant should be considered for this patient population. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Aprea Therapeutics: Research Funding; AbbVie: Consultancy, Honoraria, Other: Travel Support, Research Funding; Adaptive Biotechnologies: Consultancy, Honoraria, Other: Travel Support, Research Funding; TransThera Sciences: Research Funding; Fate Therapeutics: Research Funding; Kite, a Gilead Company: Consultancy, Honoraria, Research Funding; Ipsen: Honoraria; Loxo Oncology: Research Funding; Medisix: Research Funding; Takeda: Research Funding; Precision Biosciences: Consultancy, Honoraria, Other: Travel Support, Research Funding; Servier Pharmaceuticals LLC: Research Funding; ADC Therapeutics: Research Funding; BMS: Consultancy, Honoraria, Other: Travel Support, Research Funding; Pfizer: Research Funding; Incyte Corporation: Research Funding; Cellectis: Honoraria, Research Funding; Dialectic Therapeutics: Research Funding; Novalgen: Research Funding; Newave: Research Funding; MEI Pharma: Honoraria; TG Therapeutics: Honoraria; Beigene: Honoraria; Cellectis: Honoraria, Research Funding; Mingsight: Research Funding; Pharmacyclics, Inc.: Consultancy, Honoraria, Other: Travel Support, Research Funding; Janssen Pharmaceuticals, Inc.: Consultancy, Honoraria, Other: Travel Support; Genentech, Inc.: Consultancy, Honoraria, Other: Travel Support, Research Funding; AstraZeneca: Consultancy, Honoraria, Other: Travel Support, Research Funding; CareDx: Honoraria. Thompson: AbbVie, Gilead, Janssen, Pharmacyclics, Adaptive Biotechnologies, Genentech, Amgen: Honoraria; AbbVie, Gilead, Janssen, Pharmacyclics, Adaptive Biotechnologies, Genentech: Consultancy; Adaptive Biotechnologies: Membership on an entity’s Board of Directors or advisory committees; AbbVie, Pharmacyclics, Adaptive Biotechnologies, Genentech: Research Funding.
